Cantor Fitzgerald Starts VolitionRX (VNRX) at Overweight

Cantor Fitzgerald analyst Kyle Mikson initiates coverage on VolitionRX (NYSE: VNRX) with a Overweight rating and a price target of $8.00.

The analyst comments "We are initiating coverage of VolitionRx (VNRX) with an Overweight rating and a 12-month price target of $8. The company is developing a suite of blood-based (liquid biopsy) tests for a broad range of cancers, such as colorectal (CRC), lung and blood cancers. These products still require clinical validation and regulatory clearance, but Volition recently launched a cancer screening test for canines. The company’s tests are built on its epigenetics-based Nu.Q technology, which measures nucleosome levels in blood rather than typical liquid biopsy biomarkers such as circulating tumor DNA (ctDNA). We believe Volition’s approach could enable deeper surveillance and potentially detect cancers earlier than ctDNA-based tests. The company could have multiple revenue drivers in the near term, but we view its long-term growth potential as highly compelling. Importantly, Volition has multiple ongoing clinical trials to evaluate its tests to help obtain regulatory approvals, which are critical to its long-term outlook. We believe the company will execute its strategy and achieve robust long-term growth. At current levels, we believe the shares do not reflect the company’s long-term outlook, as we see it."

For an analyst ratings summary and ratings history on VolitionRX click here. For more ratings news on VolitionRX click here.

Shares of VolitionRX closed at $3.84 yesterday.

You May Also Be Interested In

• Singular Research Starts Citizens Inc. (CIA) at Buy-Long Term, 'Proven Distribution Growth'
• EQT Corp. (EQT) PT Lowered to $46 at Wolfe Research
• Piper Sandler Downgrades Independent Bank Group (IBTX) to Underweight, 'Expectations of Slower NII Recovery'